Because little has been published on early effects of treatment with amiodarone on thyroid function, we studied serum total and free thyroid hormone, reverse T 3 , and TSH levels in patients with cardiac arrhythmias during the first 10 days of treatment with a loading dose of amiodarone by iv infusion. Twenty-four patients were enrolled in the study. A standardized loading regimen for the iv infusion of amiodarone was used. The protocol provided the iv infusion of 20 mg/kg per day on day 1, the iv infusion of 10 mg/kg per day on day 2, then 600 mg/day per os for 7-10 days, and finally, in patients chronically treated with the drug, the dose was gradually reduced to 400 -200 mg/day per os. Total and free concentrations of T 4 tended to progressively and significantly increase (P Ͻ 0.0001 repeated measures ANOVA) starting from the fourth day of therapy, whereas total T 3 decreased from the second day progressively (P Ͻ 0.0001) throughout the study; free T 3 did not significantly change. TSH levels early and significantly (P Ͻ 0.001, by ANOVA) increased throughout the study, starting from the first day of therapy and reaching at 10 days a value 2.7 times higher than the basal value. Reverse T 3 levels progressively and significantly (after 2 days of treatment) increased and paralleled the TSH values, reaching at the 10th day a value about 2 times higher than basal value. In conclusion, our data suggest that after iv treatment with amiodarone: 1) TSH is the first hormone to change significantly followed by reverse T 3 , T 4 , and T 3 ; 2) the progressive fall of T 3 levels reflects an inhibition of the peripheral conversion of T 4 to T 3 ; 3) the observed later increase of total and free T 4 levels may be explained by a contribution of direct thyroidal stimulation by TSH and/or by a reduction in T 4 clearance. (J Clin Endocrinol Metab 82: [275][276][277][278][279][280] 1997) 
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A MIODARONE is a potent class III antiarrhythmic agent currently used for the treatment of supraventricular and ventricular arrhythmias unresponsive to conventional antiarrhythmic drugs (1) (2) (3) . It contains 75 mg iodine/200 mg active substance with a long-term daily dose generally ranging from 600 -200 mg. In view of its high iodine content, the drug was extensively studied for its possible influence on thyroid function (4 -7) . These studies demonstrated that amiodarone exerts important effects on peripheral metabolism of thyroid hormones and on thyroid function as well (1, 4) . Amiodarone has been consistently shown to inhibit peripheral conversion of T 4 to T 3 in vivo, probably because of inhibition of 5Ј-deiodinase (type 1) activity (1, 3, (5) (6) (7) . Using a double-tracer method, it has been shown (8, 9 ) that long-term therapy (lasting 6 months) with amiodarone, which is effective in suppressing arrhythmias, also reduces peripheral T 4 -T 3 conversion. Although the previous data (6 -9) clarified the effects of chronic therapy with amiodarone on thyroid hormone metabolism in patients, little information is available on the acute effects of this drug.
Earlier prospective studies on short-term effects of amiodarone have been limited to a small number of normal subjects rather than cardiac patients (10, 11) , and/or did not include data on free hormone concentrations when performed in arrhythmic patients (12) . Furthermore, most data (10 -12) on TSH release were based on relatively a insensitive RIA method and/or TRH test, which was performed under basal condition and after 4 (10) or 24 (11) weeks of treatment, respectively. One prospective study examined patients with symptomatic ventricular tachyarrhythmias treated with oral doses of amiodarone and documented effects of the amiodarone at or after 7 days of treatment; this study did not evaluate free thyroid hormone levels (13) .
Clinical interest in amiodarone has been increasing recently because of its effectiveness in a wide range of cardiac disturbances, including prophylaxis of life-threatening ventricular tachyarrhythmias in myocardial infarction survivors (sudden death cardiac prophylaxis), because it does not show the hemodynamic disadvantages of other antiarrhythmic drugs (14 -16) . More recent protocols of amiodarone treatment provide the use of an iv loading dose of the drug to rapidly reach an effective plasma concentration (14 -17) . However, to our knowledge, the mechanism of the acute interaction of the drug with the thyroid function is not well understood in amiodaronetreated arrhythmic patients.
We describe here a prospective study designed to gather information on acute changes in serum TSH and thyroid hormone levels after an iv loading dose of amiodarone in patients with cardiac arrhythmias; a group of well-matched patients, who were not treated with the drug, served as control group.
Methods

Hormone assay methods
Serum T 4 and T 3 concentrations were measured by the fully automated immunoenzymometric assay AIA 600 system (TOSOH Corp., Tokyo, Japan). Serum TSH was measured by a third-generation (sensitivity Յ 0.005 IU/mL immunoluminometric assay (ILMA) method BeriLux human TSH (Behringwerke AG, Marburg, Germany). Serum T 3 and T 4 free concentrations were measured using both the microparticle enzyme immunoassay by means of a fully automated IMx apparatus (Abbott Labs., Diagnostic Division, Abbott Park, IL) and the gel equilibration procedure (Liso Phase RIA system, Techno Genetics, Cassina de' Pecchi, Milano, Italy). Serum reverse T 3 (rT3) was measured by a RIA method (BIODATA Diagnostic, manufactured by Biodata S.p.A., Guidonia Montecelio, Roma, Italy). To minimize the assay error, each serum sample was assayed more than once in the same assay; consequently, the values used in the study are the mean result of all of these determinations. The sensitivity and between-assay precision of these methods were previously reported (8, 9) .
In our laboratory the normal ranges for serum hormone concentrations are the following: total T 4 : 58 -154 nmol/L (4.5-12 g/100 mL); total T 3 : 1.2-3.0 nmol/L (80 -200 ng/100 mL); free T 4 : 9 -24 pmol/L (7.0 -18.5 pg/mL); free T 3 : 3.9 -8.3 pmol/L (2.6 -5.4 pg/mL); TSH: 0.3-4.2 IU/mL; rT 3 : 0.14 -0.55 nmol/L (9 -35 ng/100 mL).
Amiodarone assay
Serum concentrations of amiodarone and its major metabolite Ndesethyl-amiodarone were measured by a high performance liquid chromatography method, using as internal standard the trifluoperazine, as previously described in detail (17) . Each unknown serum sample was triple assayed. The sensitivity of the assay is 0.15 g/mL of amiodarone. We considered an acceptable therapeutical range to be when the serum amiodarone levels ranged from 0.5-2 g/mL (2, 17).
Experimental subjects
Patients. Twenty-four patients who had been chosen for treatment with amiodarone because of their cardiac arrhythmia were sequentially enrolled in the study. The most important clinical data of these patients were reported in Table 1 . Five patients showed overt cardiac failure (NYHA functional class Ն III and/or left ventricular ejection fraction Ͻ20%, patients 1, 2, 6, 12, and 22 in Table 1 ); the other patients were in NYHA functional class Ͻ III or II with left ventricular ejection fraction Ն40%. Inclusion criteria were: 1) presence of cardiac arrhythmias evaluated by 48-h Holter monitoring; 2) documented inadequate efficiency of at least two different antiarrhythmic drugs; 3) absence of clinical, echographic, and laboratory evidence of thyroid diseases (including thyroid hormone concentrations and titers of antithyroid antibodies); and 4) no consumption of any other drug known to affect thyroid function. Myocardial contractility, dimensions, and function were assessed by two-dimensional echocardiography and radionuclide ventriculography. The weight of patients was monitored daily and did not significantly vary during the study.
Study protocol. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethics commission (no one refused to participate to the study). The patients were hospitalized for the time necessary to perform the study. A standardized loading regimen for the iv infusion of amiodarone was used. The protocol provided for iv infusion of 20 mg/kg per day on day 1, iv infusion of 10 mg/kg per day on day 2, then 600 mg/day per os (200 mg at 0800 h, 1400 h, and 2000 h, respectively) for 7-10 days, and finally, in patients chronically treated with the drug, the dose was gradually reduced to 400 -200 mg/day per os. When necessary, this therapeutical protocol was adjusted in each patient, following the results of amiodarone assay, to reach a relative plateau of serum amiodarone within the therapeutical range without increasing drug values above the limit toxic level (i.e. 2.5 g/mL).
In all 24 patients studied, two serum samples for amiodarone and hormonal assays were collected before the start of therapy (basal sample), and then other serum samples were collected at least every 12 h in the first 2 days after amiodarone administration and at least once a day in the following days. In 16 patients who had been hospitalized for a long time because of their cardiac disease, serum samples were also collected at 0800 h of the 10th day. Finally, in 16 patients who had been chronically treated with amiodarone, at least one other serum sample was collected 3 months after the start of therapy.
Control group. Twenty arrhythmic patients (14 men and 6 women), matched for age (66.6 Ϯ 9.8 yr; range 46 -81 yr) and gender, as well as for underlying heart disease, were enrolled in the study as the patients' control group. These patients were hospitalized in the same clinical ward and for the same period of the study as the amiodarone-treated patients; these patients, even if they suffered from cardiac arrhythmias, were not given for treatment with amiodarone and did not take any medications that may have affected thyroid function.
Serum samples for hormone assays were collected throughout 5 consecutive days in the clinical ward.
Statistical analysis
The statistical analysis was carried out by a Macintosh IIsi personal computer using the Stat-View 4.0 and SuperANOVA programs (Abacus Concepts, Berkeley, CA). Data were analyzed by ANOVA for paired data (repeated measures), and the significant differences between the pairs of means were tested by the Bonferroni/Dunn test for paired data. The results were expressed as the mean Ϯ sd in the text and as the mean Ϯ sem in the figures.
Results
Control patients
There was no significant variation in serum concentrations of TSH and of thyroid hormones (total and free concentration) throughout the 5 days of the study in the arrhythmic patients not treated with amiodarone (data not shown). Moreover, the mean hormone levels of these patients were not significantly different from basal hormone values found in patients treated with amiodarone (Table 1) .
Amiodarone-treated patients
Baseline hormone values. On average, basal levels of total and free thyroid hormones and TSH were found to be in the normal range (Table 1) . However, as expected (18, 19) , the analysis of individual values indicates that several patients (with NYHA functional class Ն III) showed evidence of euthyroid sick syndrome, as demonstrated by low levels of both total and/or free T 3 and/or T 4 concentrations (patients 1, 2, 6, 12, and 22 in Table 1 ).
Serum drug levels. The mean (Ϯ sem) time course of serum amiodarone and of its main metabolite N-desethyl-amiodarone throughout the first 10 days of therapy in patients treated with amiodarone is shown in Fig. 1 . The peak of amiodarone concentration observed in the first 12-36 h was caused by the loading iv dose of the drug. It is important to note that a detectable concentration of the main and pharmacologically active metabolite was on average found within 24 h after the start of amiodarone administration. By using the therapeutical protocol described in this study, the plateau of the circulating levels of amiodarone was generally reached in 5-12 days (on average in 9 days) (Fig. 1) . The mean concentration of amiodarone after 3 months of therapy was 0.73 Ϯ 0.25 g/mL, and that of its metabolite was 0.63 Ϯ 0.11 g/mL; the mean ratio, found in chronically treated patients (for at least 3 months) between N-desethyl-amiodarone and amiodarone concentrations was 0.84 Ϯ 0.34. All of these findings are consistent with previously described data (17) .
Serum hormone levels after amiodarone therapy
Acute effects of amiodarone administration. The time courses of the daily mean values of serum total and free T 3 and T 4 concentrations, observed in the first 10 days of therapy with amiodarone, are shown in Figs. 2 and 3 , respectively. Total and free concentrations of T 4 tended to significantly (P Ͻ 0.0001, by ANOVA) increase in the first 5 days of therapy, reaching a maximum at the fifth day after the start of therapy (free T 4 ϭ ϩ15.3% and total T 4 ϭ ϩ11.5%, on average, compared with basal values). On the contrary, total T 3 levels progressively and significantly fell throughout the study (P Ͻ 0.0001, by ANOVA), whereas free T 3 did not significantly change. However, after 10 days of therapy, the free T 3 levels were, on average, 88.4%, and the total T 3 were 81.3% compared with basal values.
The time courses of daily mean values of serum TSH and rT 3 concentrations, observed in the first 10 days of therapy with amiodarone, are shown in Fig. 4 . TSH levels early and significantly (P Ͻ 0.001, by ANOVA) increased throughout the study, starting from the first day of therapy and at 10 days reaching a value that was on average 2.7 times higher than the basal value (Fig. 4) . rT 3 levels progressively and significantly (after 2 days of treatment) increased and paralleled the TSH values, at the 10th day reaching a value that was about two times higher than basal value (Fig. 4) .
Chronic effects of amiodarone therapy. In the 16 patients who were able to continue the amiodarone treatment for more than 3 months, mean serum TSH (5.8 Ϯ 7.9 IU/mL vs. 2.6 Ϯ 2.2 IU/mL, P Ͻ 0.001) and rT 3 (67.5 Ϯ 23.0 ng/100 mL vs. 30.8 Ϯ 11.0 ng/100 mL, P Ͻ 0.0001) were higher than basal value, whereas total T 3 remained significantly lower than basal value (88.9 Ϯ 21.4 ng/100 mL vs. 102.2 Ϯ 21.5 ng/100 mL, P Ͻ 0.001). Moreover, mean serum free T 3 tended to come back to basal value (3.8 Ϯ 1.0 pg/mL vs. 3.5 Ϯ 0.9 pg/mL), whereas T 4 values were found to be slightly higher than basal value (total T 4 : 8.8 Ϯ 2.1 g/100 mL vs. 7.8 Ϯ 1.8 g/100 mL, and free T 4 : 12.1 Ϯ 3.2 pg/mL vs. 11.1 Ϯ 3.1 pg/mL, respectively).
Discussion
Only a few studies (10, 11) have investigated the early effects of amiodarone on thyroid function. One study was performed in nine healthy young adult subjects (all men, aged 25-40 yr), who received 400 mg per os for 28 days (10) . This protocol did not provide the time courses of free concentrations of thyroid hormones (only serum free T 3 was measured 11 days before and at 2 and 28 days after commencement of treatment) and amiodarone or its main metabolite during the early days of treatment with the drug.
Furthermore, the protocol of amiodarone administration differs markedly from that currently employed in the treatment of patients with cardiac arrhythmias (2, 14 -16) . In fact, because of the long biological half-life of amiodarone, a loading dose of drug is currently recommended to rapidly reach therapeutic circulating levels of the drug (2, 14 -17). Moreover, although there is a linear relationship between oral doses of amiodarone and drug concentrations in plasma and myocardial tissue, the concentrations in patients taking the same dose vary markedly, and therefore monitoring drug concentration is considered important to achieve maximal therapeutic effects and to minimize possible side effects (14 -17) . For these reasons, the results found in the previous study (10) in normal subjects may be not directly extrapolated to arrhythmic patients treated with modern-day regimens of amiodarone.
Our studies describe the early effects of amiodarone treatment in arrhythmic patients. Our findings indicate that in arrhythmic patients short-term amiodarone treatment induced a significant decrease in serum total T 3 . Interestingly, in our patients free T 3 showed a pattern not parallel to that of total T 3 , mainly in the first 4 days of treatment (Fig. 2) . The basis for this observation is not known. This finding may reflect the displacement by amiodarone of T 3 bound to serum proteins (15) .
It is noteworthy that, unlike previous data in normal sub- jects (10), which showed an early decline in T 4 concentrations, our data showed a significant increase in plasma T 4 (both total and free) with the drug; a similar tendency for total T 4 increase was also previously observed in arrhythmic patients after 7 days of treatment with an oral dose of amiodarone by other authors (13) . The early decline of T 4 concentrations in normal subjects given amiodarone has been suggested to be responsible for the subsequent increase in TSH (20) . However, our data do not support this possibility. We have documented a rise in serum TSH concentration in our patients earlier (first day) than previously reported in normal subjects (second day) (10) or arrhythmic patients (eighth day) (12) . It is not clear whether this discrepancy can be related to the different modality (oral vs. iv) and/or amount of drug administration, improved TSH techniques, the difference in the study population, and/or a more frequent collection of blood samples in the first days of the study. Indeed, by frequent sampling, we were able to clearly show that TSH is the first hormonal parameter to be affected by amiodarone administration. The use of a third-generation assay for TSH measurement provided a suitable sensitivity to determine the minimal hormonal changes observed after amiodarone treatment. An increment of 39%, on average, was found in serum TSH at 24 h of treatment, and a significant increment (65%) of TSH levels was clearly demonstrated on the second day of amiodarone administration (Fig.  4) . The basis for the measured TSH increase after amiodarone is not known. It may be caused by an early inhibition of type II 5Ј-deiodinase in the pituitary cells; other possible effects may include a direct TSH secretory effect of the drug and a competition between amiodarone, its metabolite, and specific nuclear receptors for T 3 (3) . In this respect, there are indications that desethylamiodarone (and not amiodarone) competes with T 3 for receptors in most tissues (21) . Our data showing a rapid appearance of desethylamiodarone in plasma within 24 h after iv amiodarone, and the parallel rise with the rise of TSH levels lend further support to this possibility.
The later increase in the serum total T 4 and free T 4 levels (which reach statistical significance at 4 days) may be explained by a direct stimulation of T 4 secretion by increased TSH. However, in the absence of kinetic studies, it is not possible to exclude an important role of an alteration in T 4 to T 3 metabolism (5).
The progressive significant increase in rT 3 , as well as the concomitant and parallel fall in serum total T 3 levels, which reach a statistical significance after 48 h of treatment, suggest an inhibition by amiodarone or its metabolite of type I 5Ј deiodinase resulting in a decrease in peripheral conversion of T 4 to T 3 and metabolic clearance of rT 3 .
The inhibitory action of amiodarone on iodothyronine deiodinase activity seems to persist during chronic treatment with the drug, as demonstrated by a persistent increase of TSH and rT 3 associated with some decrease in total T 3 concentrations. This is in accordance with our previous doubletracer kinetic study in which a direct measurement of T 4 to T 3 conversion was performed before and during chronic amiodarone treatment, and an inhibition of T 4 to T 3 peripheral conversion was demonstrated (9) . These alterations in thyroid hormone metabolism may contribute to changes observed during the first 24 -120 h after amiodarone iv loading dose in this study. 3 and TSH concentrations observed in first 10 days of therapy with amiodarone in patients cardiac arrhythmia. Number of patients studied in each day is reported in parentheses. Statistical significance (by Bonferroni/Dunn test after ANOVA, repeated measures) compared with basal values is also noted.
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